Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Follow-Up Questions
Scienture Holdings Inc (SCNX) 的本益比是多少？
Scienture Holdings Inc 的本益比是 2.0214
Scienture Holdings Inc 的 CEO 是誰？
Mr. Surendra Ajjarapu 是 Scienture Holdings Inc 的 Chairman of the Board，自 2014 加入公司。
SCNX 股票的價格表現如何？
SCNX 的當前價格為 $0.935，在上個交易日 increased 了 5.17%。
Scienture Holdings Inc 的主要業務主題或行業是什麼？
Scienture Holdings Inc 屬於 Health Care 行業，該板塊是 Health Care
